Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Ovarian Cancer
Has your preferred adjuvant treatment for IC mucinous ovarian cancer changed in response to the platinum chemotherapy shortage?
Answer from: at Community Practice
We previously offered observation to Stage IC low grade mucinous ovarian cancer so this has not impacted our decision.
Sign in or Register to read more
17555
Related Questions
What second-line therapy would you recommend for a patient with a pathogenic BRCA-1 mutation and stage IIIA fallopian tube high-grade serous carcinoma, who underwent R0 cytoreduction followed by 6 cycles of carboplatin/paclitaxel with complete response, who has now progressed 13 months into olaparib maintenance?
How would you manage a patient with an incidental finding of 1 mm focus of high-grade serous carcinoma in the fallopian tube after TAHBSO was done for a benign broad ligament fibroid with negative pelvic washings?
How do you factor a decreasing but persistently elevated CA-125 into your decision regarding whether to proceed with interval cytoreductive surgery for PAX8+ high-grade serous cancer s/p neoadjuvant chemotherapy with minimal disease on imaging?
For patients with ovarian cancer, do you order folate receptor-alpha testing at initial diagnosis, first recurrence, or first instance of platinum resistance?
Have you had patients who wish to take ivermectin and/or fenbendazole as adjunct treatments for gynecologic cancers and if so, how have you handled this?
Would you favor giving mirvetuximab before paclitaxel/bevacizumab?
How do you incorporate a KELIM score into your management of patients with ovarian cancer?
What are your top takeaways in Gyn Cancers from ESMO 2024?
Would you ever re-treat recurrent ovarian cancer with mirvetuximab soravtansine if the patient responded to it in the past (e.g., more than 6 months ago)?
How do you manage patients with germline BRCA mutations who have STIC lesions found at the time of risk-reducing BSO?